In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66-and
placebo-vaccinated children were analyzed by polymerase chain reaction-restriction …

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum
malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical …

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66
vaccine is based on pre-erythrocytic and asexual blood-stage proteins of Plasmodium …

Combination B is a malaria vaccine that comprises recombinant Plasmodium falciparum (P.
falciparum) blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant …

The malaria vaccine Combination B comprises recombinant Plasmodium falciparum ring-
infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) …

SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-
erythrocytic and asexual blood-stage proteins of Plasmodium falciparum. SPf66 was found …

Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …

To facilitate design of vaccine trials, malaria was studied in 6-month-to 6-year-old Kenyans
during high (HI) and low intensity transmission seasons. During 84 days after cure, exposure …

Background Malaria vaccines based on the 19-kDa region of merozoite surface protein 1
(MSP-119) derived from the 3D7 strain of Plasmodium falciparum are being tested in clinical …

Objective The antigen, falciparum malaria protein 1 (FMP1), represents the 42-kDa C-
terminal fragment of merozoite surface protein-1 (MSP-1) of the 3D7 clone of P. falciparum …